A-SPINE Asia Co (6758) Fair Value & Analysis
Healthcare · TW · Market cap 394M TWD
Fair value as of: Jul 23, 2026
From 25 valuation models · updated 18 days ago
Share price −0.4% over the past month.
A solid business, but screening 33% overvalued on our models.
What matters now
- A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (25.47 TWD). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 27.04 TWD – 46.49 TWD · fair‑value band 14.27 TWD – 25.47 TWD · the 28.85 TWD price screens above the 19.31 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
A-SPINE Asia Co (6758) currently trades at 28.85 TWD, while our model-based Fair Value estimate is 19.31 TWD, implying the stock looks roughly 33.1% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Net debt stands at 71.8M TWD. The stock trades on a trailing P/E of 27.0. Fundamentals as of Jul 23, 2026
Our scenario range runs from 14.27 TWD (bear case) to 25.47 TWD (bull case); at 28.85 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -33%, 6758 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (25.99 TWD) versus Dividend Discount (11.29 TWD). Highest evidence: Growth DCF (80).
Notify me when 6758 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
A-SPINE Asia Co., Ltd., a medical device company, engages in the research, development, manufacture, and marketing of spinal implants and instruments in Taiwan, China, the Philippines, Australia, New Zealand, Iran, Vietnam, Indonesia, Spain, Trinidad, and Sri Lanka.
Full company description
A-SPINE Asia Co., Ltd., a medical device company, engages in the research, development, manufacture, and marketing of spinal implants and instruments in Taiwan, China, the Philippines, Australia, New Zealand, Iran, Vietnam, Indonesia, Spain, Trinidad, and Sri Lanka. The company offers spinal fixation systems, such as cervical anterior fixation, and thoracic and lumbar fixation systems; interbody fixation systems, including ACDF cages, PLIF/TLIF cages, and ALIF cages; balloon kyphoplasty products; and vertebral body replacement products. It sells imported orthopedic medical devices. A-SPINE Asia Co., Ltd.was founded in 2001 and is based in New Taipei City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
A-SPINE Asia Co reported revenue of 449M TWD in FY2025 versus 310M TWD in FY2021, a compound +9.7%/yr. Reported net income was 15.1M TWD in FY2025, compounding −4.0%/yr from FY2021.
6758 screens 33% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare A-SPINE Asia Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is A-SPINE Asia Co (6758) overvalued or undervalued?
What is the fair value of 6758?
What is the quality score of 6758?
What is the net profit margin of 6758?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track A-SPINE Asia Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.